CompletedPhase 2

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

United States281 participantsStarted 2020-07-28

Plain-language summary

Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp\[a\]).

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 to 80 years * Lipoprotein (a) \> 150 nmol/L * Evidence of atherosclerotic cardiovascular disease Exclusion Criteria: * Severe renal dysfunction * History or clinical evidence of hepatic dysfunction * Malignancy within the last 5 years * Currently receiving, or less than 3 months at Day 1 since receiving \> 200 mg/day Niacin

What they're measuring

Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36

Timeframe: Baseline and Week 36

Trial details

NCT IDNCT04270760

SponsorAmgen

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-12-27

Results submitted2023-08-01

View on ClinicalTrials.gov More Cardiovascular Disease trials